Literature DB >> 11578488

5T4 oncofetal antigen expression in ovarian carcinoma.

E. Wrigley1, A.T. McGown, J. Rennison, R. Swindell, D. Crowther, T. Starzynska, P.L. Stern.   

Abstract

5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P < 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease-free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.

Entities:  

Year:  1995        PMID: 11578488     DOI: 10.1046/j.1525-1438.1995.05040269.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  26 in total

1.  Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

Authors:  Irina Redchenko; Richard Harrop; Matthew G Ryan; Robert E Hawkins; Miles W Carroll
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

2.  Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen.

Authors:  David M Shaw; Andrew M Woods; Kevin A Myers; Caroline Westwater; Veena Rahi-Saund; Michael J Davies; David V Renouf; Elizabeth F Hounsell; Peter L Stern
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

3.  Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.

Authors:  Andrew M Woods; Who W Wang; David M Shaw; Christopher M Ward; Miles W Carroll; Buddug R Rees; Peter L Stern
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

4.  5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma.

Authors:  Samuel A Kerk; Kelsey A Finkel; Alexander T Pearson; Kristy A Warner; Zhaocheng Zhang; Felipe Nör; Vivian P Wagner; Pablo A Vargas; Max S Wicha; Elaine M Hurt; Robert E Hollingsworth; David A Tice; Jacques E Nör
Journal:  Clin Cancer Res       Date:  2016-10-25       Impact factor: 12.531

Review 5.  Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.

Authors:  Scott S Tykodi; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

6.  CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.

Authors:  Thomas D Southgate; Owen J McGinn; Fernanda V Castro; Andrzej J Rutkowski; Mariam Al-Muftah; Georgi Marinov; Graeme J Smethurst; David Shaw; Christopher M Ward; Crispin J Miller; Peter L Stern
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

7.  E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells.

Authors:  Helen L Spencer; Angela M Eastham; Catherine L R Merry; Thomas D Southgate; Flor Perez-Campo; Francesca Soncin; Sarah Ritson; Rolf Kemler; Peter L Stern; Christopher M Ward
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

8.  Evolving Strategies for Target Selection for Antibody-Drug Conjugates.

Authors:  Marc Damelin; Wenyan Zhong; Jeremy Myers; Puja Sapra
Journal:  Pharm Res       Date:  2015-01-15       Impact factor: 4.580

9.  Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

Authors:  Howard L Kaufman; Bret Taback; William Sherman; Dae Won Kim; William H Shingler; Dorota Moroziewicz; Gail DeRaffele; Josephine Mitcham; Miles W Carroll; Richard Harrop; Stuart Naylor; Seunghee Kim-Schulze
Journal:  J Transl Med       Date:  2009-01-07       Impact factor: 5.531

10.  Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.

Authors:  Rabih Said; Robert J Amato
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.